Jacobs Levy Equity Management’s Arcturus Therapeutics ARCT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.53M	Sell	198,728 -94,322	-32%	-$688K	0.01%	630
2025 Q4	$1.8M	Sell	293,050 -12,609	-4%	-$136K	0.01%	599
2025 Q3	$5.63M	Sell	305,659 -189,632	-38%	-$3.05M	0.02%	405
2025 Q2	$6.44M	Buy	495,291 +351,150	+244%	+$4.15M	0.03%	381
2025 Q1	$1.53M	Buy	144,141 +24,583	+21%	+$390K	0.01%	720
2024 Q4	$2.03M	Buy	119,558 +19,859	+20%	+$374K	0.01%	587
2024 Q3	$2.31M	Sell	99,699 -637	-0.6%	-$13.6K	0.01%	575
2024 Q2	$2.44M	Buy	100,336 +4,412	+5%	+$134K	0.01%	571
2024 Q1	$3.24M	Buy	95,924 +50,470	+111%	+$1.79M	0.01%	507
2023 Q4	$1.43M	Buy	45,454 +36,128	+387%	+$859K	0.01%	660
2023 Q3	$238K	Sell	9,326 -7,912	-46%	-$244K	﹤0.01%	906
2023 Q2	$494K	Buy	+17,238	New	+$469K	﹤0.01%	826

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's ARCT Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Arcturus Therapeutics (ARCT) stake by 32% in Q1 2026, selling an estimated $688K and leaving 198,728 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #630.

Jacobs Levy Equity Management first reported a position in ARCT in Q2 2023 and has held it in 12 quarters since. The position peaked at $6.44M in Q2 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

Jacobs Levy Equity Management held 198,728 shares of Arcturus Therapeutics worth $1.53M as of Q1 2026.
Jacobs Levy Equity Management sold 94,322 Arcturus Therapeutics shares in Q1 2026, an estimated $688K.
Arcturus Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #630 holding.
Jacobs Levy Equity Management first reported a position in Arcturus Therapeutics in Q2 2023 and has held it in 12 quarters since.
Jacobs Levy Equity Management's Arcturus Therapeutics position peaked at $6.44M in Q2 2025.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.